2026-01-28 - Analysis Report
## Financial Report for Regeneron Pharmaceuticals (REGN)

### Overview of Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a multinational biotechnology company that develops and commercializes medicines for serious diseases.

### Comparison of Return Rates

* **Cumulative Return**: REGN = 53.78%, VOO = 128.51%
	+ Degree of Divergence: -75.50 (21.10% relative to the minimum-maximum fluctuation range)
* **Recent Periods**:
	+ 2016-2018: -3.0% CAGR, 24.1% MDD, -12.0% Alpha, 39.6B Cap
	+ 2017-2019: 9.0% CAGR, 27.3% MDD, -16.0% Alpha, 39.8B Cap
	+ 2018-2020: 31.0% CAGR, 27.3% MDD, 7.0% Alpha, 51.2B Cap
	+ 2019-2021: 40.0% CAGR, 27.3% MDD, -25.0% Alpha, 66.9B Cap
	+ 2020-2022: 72.0% CAGR, 25.7% MDD, 68.0% Alpha, 76.5B Cap
	+ 2021-2023: 61.0% CAGR, 24.4% MDD, 43.0% Alpha, 93.1B Cap
	+ 2022-2024: -1.0% CAGR, 40.5% MDD, -30.0% Alpha, 75.5B Cap
	+ 2023-2025: -17.0% CAGR, 57.2% MDD, -92.0% Alpha, 81.8B Cap

### Recent Stock Price Fluctuations

* Close: $771.25
* Last-market: +1.13% (previous close: $762.65)
* Moving Averages:
	+ SMA (5-day): $758.46
	+ SMA (20-day): $766.72
	+ SMA (60-day): $736.05

### Technical Indicators

* Market Risk Indicator (MRI): 0.70 (Medium Investment)
* RSI: 48.32
* PPO: -0.30
* Hybrid Signal: Buy (Cash 0%)
* Relative Divergence Change (20 days): +3.40 (improving)
* 7-day Rank change: +12 (rank up)
* 7-day Dynamic Expected Return change: +45.20 (improving)
* Expected Return: 6.10%

### Recent News & Significant Events

* 2026-01-27: Regeneron (REGN) Posted Solid Quarterly Results, Eyes 2026 Pipeline Catalysts (Yahoo Finance)
* 2026-01-02: Regeneron Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on January 30, 2026 (Quiver Quantitative)
* 2026-01-27: Lbp Am Sa Grows Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat (MarketBeat)
* 2026-01-11: A big Wall Street flip just changed the Regeneron narrative - thestreet.com (theStreet.com)
* 2026-01-27: Regeneron stock price target maintained by RBC on competitive outlook - Investing.com (Investing.com)
* 2026-01-23: REGN or ILMN: Which Is the Better Value Stock Right Now? - Nasdaq (Nasdaq)

### Analyst Opinions

* Key: Buy
* Mean (1=StrongBuy~5=Sell): 1.69
* Opinions: 26
* Target Price (avg/high/low): $831.38 / $1057.00 / $630.00

### Recent Earnings Analysis

| Date | EPS | Revenue |
|----|----|----|
| 2025-10-28 | 14.09 | $3.75 B |
| 2025-08-01 | 13.24 | $3.68 B |
| 2025-04-29 | 7.58 | $3.03 B |
| 2024-10-31 | 12.4 | $3.72 B |
| 2025-10-28 | 12.4 | $3.72 B |

### Revenue and Profitability

 Revenue and Profitability:

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $3.75 B | 86.11% |
| 2025-06-30 | $3.68 B | 85.58% |
| 2025-03-31 | $3.03 B | 84.67% |
| 2024-12-31 | $3.79 B | 85.08% |
| 2024-09-30 | $3.72 B | 86.80% |

### Capital and Profitability

 Capital and Profitability:

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $30.96 B | 4.72% |
| 2025-06-30 | $29.94 B | 4.65% |
| 2025-03-31 | $29.39 B | 2.75% |
| 2024-12-31 | $29.35 B | 3.13% |
| 2024-09-30 | $29.33 B | 4.57% |

## Comprehensive Analysis (Summary of Previous Items)

* The cumulative return of REGN is lower than the S&P 500 (VOO) by 75.50 (21.10% relative to the minimum-maximum fluctuation range).
* Recent earnings have been strong, with EPS increasing to 14.09 and revenue reaching $3.75 B in the latest quarter.
* The company has a solid pipeline of products and expects to see catalysts in 2026.
* Analysts are generally positive, with a mean rating of 1.69 and a target price of $831.38.
* The hybrid signal indicates a buy signal with 0% cash allocation.
* Technical indicators suggest a medium investment risk.
* Expected return is 6.10%, and the expected excess return compared to the S&P 500 is higher.
* Revenue and profitability are strong, with a profit margin of 86.11% in the latest quarter.
* Capital and profitability are also strong, with an ROE of 4.72% in the latest quarter.

Overall, the analysis suggests that Regeneron Pharmaceuticals (REGN) has a strong financial position and is expected to see growth in the future. However, the return rate is lower than the S&P 500, and the expected excess return is not high. Therefore, investors should carefully consider their investment decisions based on their individual risk tolerance and financial goals.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.